Universität Münster
2 clinical trials · 2 recruiting · OTHER
Trials by Universität Münster
RECRUITINGPhase 1 / Phase 2NCT05590689
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
The investigational drug 5-ALA (known under the trade name Gliolan®) is an approved drug for the surgical removal of malignant glioma (WHO grade III and IV). In this trial, the...
Sponsor: Universität MünsterEnrolling: 341 location
Glioblastoma
RECRUITINGNCT06095713
German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With...
Pegunigalsidase-alfa may represent an advance in ERT for FD, based on its unique pharmacokinetics and apparent low immunogenicity. The objective of the study is to document long...
Sponsor: Universität MünsterEnrolling: 608 locations
Fabry Disease